Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.51 |
| ▸ | CCR6 | P51684 | 9/20 | 0.49 |
| ▸ | DPP4 | P27487 | 4/20 | 0.49 |
| ▸ | CCNK | O75909 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1031708 | 1.00 | PRKCI (0.51) | PRKCICCR6DPP4CCNKCCNA2 | |
| Hydrochloric Acid SCHEMBL28555884 | 0.99 | PRKCI (0.50) | PRKCICCR6DPP4CCNKCCNA2 | |
| Hydrochloric Acid SCHEMBL28555877 | 0.99 | PRKCI (0.50) | PRKCICCR6DPP4CCNKCCNA2 | |
| SCHEMBL1119511 | 0.92 | IRAK4 (0.54) | CCR6DPP4CCNKCCNA2CDK2 | |
| SCHEMBL2709498 | 0.91 | CCR6 (0.54) | CCR6DPP4CCNKCCNA2CDK2 | |
| Hydrochloric Acid SCHEMBL1514111 | 0.90 | IRAK4 (0.53) | CCR6DPP4CCNKCCNA2CDK2 | |
| Hydrochloric Acid SCHEMBL3608266 | 0.90 | IRAK4 (0.53) | CCR6DPP4CCNKCCNA2CDK2 | |
| Hydrochloric Acid SCHEMBL2418183 | 0.90 | CCR6 (0.53) | CCR6DPP4CCNKCCNA2CDK2 | |
| SCHEMBL26122679 | 0.89 | DPP4 (0.50) | CCR6DPP4CCNKCCNA2CDK2 | |
| Hydrochloric Acid SCHEMBL21521421 | 0.88 | DPP4 (0.49) | CCR6DPP4CCNKCCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828985-B2 | Carbamate and urea inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130244994-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | CLAREMON DAVID A (US) | 2013-09-19 | — | — | US | disclosed |
| US-8399504-B2 | Carbamate and urea inhibitors of 11Beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110112062-A1 | Carbamate And Urea Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC | 2011-05-12 | — | — | US | disclosed |
| EP-2276730-A2 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009131669-A2 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244994-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD17B1 | PRKCI 848/4885CCR6 3615/4885DPP4 735/4885 |
| US-20110112062-A1 | Carbamate And Urea Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD3B1, HSD17B1 | PRKCI 994/4885CCR6 3087/4885DPP4 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.